Bayer Prevails in Cross-Border FLANAX Trademark Dispute Against Belmora in U.S. Courts

The long-running trademark dispute between Bayer AG and Belmora LLC over the FLANAX mark has culminated in a significant ruling with broad implications for international trademark owners operating across borders. A U.S. District Court judge in the Eastern District of Virginia granted Bayer’s motion for summary judgment, dismissing Belmora’s claims to the FLANAX trademark in the United States.

Bayer uses the FLANAX mark in Mexico for its popular naproxen-based pain medication, known elsewhere as Aleve. Belmora sought to market its own naproxen product under the FLANAX mark in the U.S., but Bayer successfully blocked this effort. The court’s ruling also affirmed a prior decision by the Trademark Trial and Appeal Board (TTAB) that cancelled Belmora’s U.S. registration for FLANAX, which Belmora had obtained in 2005.

The United States Court of Appeals for the Fourth Circuit had earlier held that Bayer’s claims under the Lanham Act for unfair competition (§43(a)) and cancellation (§14(3)) were authorized, despite Bayer’s use of FLANAX being limited to Mexico and not the U.S. This precedent established that foreign trademark holders can bring Lanham Act claims in the U.S. based on commercial use of the mark abroad, even without domestic use.

This ruling departs from traditional legal doctrine that trademark rights are territorially confined. Previously, a mark used exclusively in Mexico by one company could be freely used by another in the U.S. without infringement concerns. However, the Fourth Circuit recognized that Bayer’s FLANAX mark’s use in Mexico created consumer recognition among Mexican-American immigrants in the U.S., who might be misled by Belmora’s use of the same mark domestically.

The Fourth Circuit emphasized there is “no unstated requirement” for prior U.S. use to establish standing under the Lanham Act, thereby blurring strict territorial boundaries and enabling companies to enforce foreign-derived trademark rights in U.S. courts.

The TTAB’s role was pivotal in this dispute. In 2014, the Board cancelled Belmora’s FLANAX registration, concluding that Belmora’s use was a deliberate attempt to trade on Bayer’s reputation established in Mexico. The TTAB found that Belmora’s marketing materials explicitly targeted Latino consumers familiar with Bayer’s FLANAX brand, constituting a “blatant misuse” designed to mislead U.S. consumers.

Specifically, the TTAB noted that Belmora’s promotional content described FLANAX as a “highly recognized top-selling brand among Latinos,” reinforcing the likelihood of consumer confusion. The Board concluded that consumers would reasonably believe Belmora’s product was licensed or produced by Bayer, given the longstanding use of FLANAX south of the border.

The District Court upheld the TTAB’s findings, rejecting Belmora’s attempts to introduce new evidence and deferring to the Board’s expertise. This deference highlights the TTAB’s importance as a primary forum for trademark disputes, offering a streamlined process for discovery and resolution compared to federal district courts.

While the TTAB’s jurisdiction is limited to registration issues and does not extend to injunctive relief or damages, its decisions carry significant weight in subsequent infringement litigation. Defendants often reconsider continued use when faced with adverse TTAB rulings, especially in cases involving bad faith or copying, as demonstrated here.

Beyond the legal outcomes, the Bayer-Belmora FLANAX case offers critical lessons for international trademark owners. It underscores the necessity of comprehensive trademark clearance that includes consideration of foreign marks, particularly those well-known in immigrant or niche communities within the U.S.

The dispute also highlights the importance of active policing of trademarks across jurisdictions. Awareness of competitors’ use and timely enforcement actions are essential to preserving rights and avoiding time-barred claims. Bayer’s delay in initiating district court litigation resulted in some claims being barred by statutes of limitation, illustrating the risks of inaction.

Trademark watching and monitoring services can provide early detection of potentially infringing uses, enabling prompt and strategic responses. This case exemplifies how cross-border trademark enforcement requires vigilance and a proactive approach to protect brand integrity in a global marketplace.

The full opinion from the U.S. District Court for the Eastern District of Virginia is publicly available for review, providing detailed insight into the court’s reasoning and the evolving landscape of international trademark law enforcement in the United States.